123 related articles for article (PubMed ID: 10849444)
1. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors.
Verdier F; Walrafen P; Hubert N; Chretien S; Gisselbrecht S; Lacombe C; Mayeux P
J Biol Chem; 2000 Jun; 275(24):18375-81. PubMed ID: 10849444
[TBL] [Abstract][Full Text] [Related]
2. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein.
Verdier F; Chrétien S; Muller O; Varlet P; Yoshimura A; Gisselbrecht S; Lacombe C; Mayeux P
J Biol Chem; 1998 Oct; 273(43):28185-90. PubMed ID: 9774439
[TBL] [Abstract][Full Text] [Related]
3. Both proteasomes and lysosomes degrade the activated erythropoietin receptor.
Walrafen P; Verdier F; Kadri Z; Chrétien S; Lacombe C; Mayeux P
Blood; 2005 Jan; 105(2):600-8. PubMed ID: 15358619
[TBL] [Abstract][Full Text] [Related]
4. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation.
Bouscary D; Pene F; Claessens YE; Muller O; Chrétien S; Fontenay-Roupie M; Gisselbrecht S; Mayeux P; Lacombe C
Blood; 2003 May; 101(9):3436-43. PubMed ID: 12506011
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis.
Tauchi T; Damen JE; Toyama K; Feng GS; Broxmeyer HE; Krystal G
Blood; 1996 Jun; 87(11):4495-501. PubMed ID: 8639815
[TBL] [Abstract][Full Text] [Related]
6. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.
Arcasoy MO; Harris KW; Forget BG
Exp Hematol; 1999 Jan; 27(1):63-74. PubMed ID: 9923445
[TBL] [Abstract][Full Text] [Related]
7. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction.
Sawyer ST; Penta K
J Biol Chem; 1996 Dec; 271(50):32430-7. PubMed ID: 8943308
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin.
Yen CH; Yang YC; Ruscetti SK; Kirken RA; Dai RM; Li CC
J Immunol; 2000 Dec; 165(11):6372-80. PubMed ID: 11086075
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.
Ungureanu D; Saharinen P; Junttila I; Hilton DJ; Silvennoinen O
Mol Cell Biol; 2002 May; 22(10):3316-26. PubMed ID: 11971965
[TBL] [Abstract][Full Text] [Related]
10. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II-induced down-regulation of inositol trisphosphate receptors in WB rat liver epithelial cells. Evidence for involvement of the proteasome pathway.
Bokkala S; Joseph SK
J Biol Chem; 1997 May; 272(19):12454-61. PubMed ID: 9139693
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway.
Yoon D; Watowich SS
Exp Hematol; 2003 Dec; 31(12):1310-6. PubMed ID: 14662339
[TBL] [Abstract][Full Text] [Related]
13. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.
Sulahian R; Cleaver O; Huang LJ
Blood; 2009 May; 113(21):5287-97. PubMed ID: 19336760
[TBL] [Abstract][Full Text] [Related]
14. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
[TBL] [Abstract][Full Text] [Related]
15. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2.
Sasaki A; Yasukawa H; Shouda T; Kitamura T; Dikic I; Yoshimura A
J Biol Chem; 2000 Sep; 275(38):29338-47. PubMed ID: 10882725
[TBL] [Abstract][Full Text] [Related]
16. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling.
Arai A; Kanda E; Nosaka Y; Miyasaka N; Miura O
J Biol Chem; 2001 Aug; 276(35):33282-90. PubMed ID: 11443118
[TBL] [Abstract][Full Text] [Related]
17. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
Witthuhn BA; Quelle FW; Silvennoinen O; Yi T; Tang B; Miura O; Ihle JN
Cell; 1993 Jul; 74(2):227-36. PubMed ID: 8343951
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
Arcasoy MO; Karayal AF
Biochim Biophys Acta; 2005 Apr; 1740(1):17-28. PubMed ID: 15878737
[TBL] [Abstract][Full Text] [Related]
19. Jak2 and proteasome activities control the availability of cell surface growth hormone receptors during ligand exposure.
Moulin S; Bouzinba-Segard H; Kelly PA; Finidori J
Cell Signal; 2003 Jan; 15(1):47-55. PubMed ID: 12401519
[TBL] [Abstract][Full Text] [Related]
20. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains.
Lu X; Gross AW; Lodish HF
J Biol Chem; 2006 Mar; 281(11):7002-11. PubMed ID: 16414957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
